Precigen Inc. (PGEN) has emerged as a notable biotechnology company following the full FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis in August 2025. With commercial momentum building, payer coverage expanding, and long-term durability data reinforcing the therapy's impact, attention now shifts to the company's upcoming catalysts.
These include the ongoing European regulatory review, further adoption metrics from the PAPZIMEOS Patient Hub, and clinical progress across its AdenoVerse immunotherapy pipeline. Together, these milestones have the potential to shape the company's trajectory in both the near and medium term.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com